Following the initial discovery of synthetic lethality between PARP inhibition and BRCA1 or BRCA2 deficiency, other cancer types that harbor mutations in genes functioning in the DDR and DNA repair networks were also shown to be sensitive to PARP inhibition44. The gene discussed is BRCA2; the disease is cancer.